Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Alembic Pharmaceuticals Limited develops, manufactures, and markets pharmaceutical products in India and internationally. The company provides branded specialty medicines in various therapeutic areas, such as cardiology, gynecology, gastrology, ophthalmology, dermatology, nephrology/urology, orthopedics, anti-infective, cold and cough, veterinary, and anti-diabetic; generics formulations in oral solids, oncology oral solids and injectables, general injectables and ophthalmic products, dermatology, and oral suspension; and active pharmaceutical ingredients. It also exports its products. The company was founded in 1907 and is headquartered in Vadodara, India.

Revenue projections:

Revenue projections for APLLTD
Revenue projections for APLLTD

Alembic Pharmaceuticals Limited's revenue projections show a decrease from last year, which tends to make investors more cautious. This could have a negative impact on the company's bottom line, as lower revenues typically suggest reduced profitability and growth potential, prompting concern among investors.

Financial Ratios:

currentRatio 1.76300
forwardPE 14.95836
debtToEquity 25.22400
earningsGrowth 0.29200
revenueGrowth 0.04400
grossMargins 0.72982
operatingMargins 0.07541
trailingEps 34.34000
forwardEps 48.50131

APLLTD's current ratio of 1.763 indicates strong liquidity, meaning the company can comfortably meet its short-term debt obligations. This financial position reflects APLLTD's ability to use its cash reserves and current assets to cover liabilities without facing any cash flow issues.
APLLTD's Forward PE is at a healthy level, meaning the stock price is aligned favorably with earnings. This suggests that the stock isn't overpriced, providing room for growth and making it an appealing option for investors looking to capitalize on potential future gains.
APLLTD's low Debt-to-Equity ratio shows that the company isn't heavily reliant on debt for financing. This implies a conservative approach to leveraging, reducing financial risk and demonstrating a solid financial foundation, which can enhance investor confidence in the company's long-term stability.
APLLTD's forward EPS is higher than its trailing EPS, which signals that the company is expected to achieve greater profitability this financial year. This suggests improved earnings performance, indicating a positive outlook for APLLTD's financial growth.

Price projections:

Price projections for APLLTD
Price projections for APLLTD

The price of APLLTD has consistently been close to the lower limit of expectations. This trend may point to challenges in the company's performance, leading to concerns about its future growth potential.

Insider Transactions:

Insider Transactions for APLLTD
Insider Transactions for APLLTD


There were 13 buy transactions of APLLTD stock, with market price at 916.6384652944712 per share.Throughout the period under consideration, no buy transactions were recorded.APLLTD's current price levels are experiencing more selling activity, which could signal bearish sentiment. If this trend continues, it may lead to further price declines, as increased selling pressure typically indicates investor concerns about the stock's future performance.

Recommendation changes over time:

Recommendations trend for APLLTD
Recommendations trend for APLLTD


Analysts are favoring APLLTD with a buy bias, highlighting the stock's potential as a solid investment. This recommendation might drive more investors to consider APLLTD as a secure and profitable option for their money, contributing to a broader positive sentiment in the market.